Table 3.
Clinical features of GOS sensitized subjects.
| No | Age of onset (years) | Dose eliciting reaction (gram) | Symptoms | Time to onset of symptom (minutes) | SPT (mm) | ||
|---|---|---|---|---|---|---|---|
| vGOS | Blo t | Der p | |||||
| S1# | 26 | 0.7 | AE, RS, Resp | 40 | 5 × 5 | 5 × 4 | 5 × 5 |
| S2# | 13 | 1.5 | AE, LU, GI, Respi | 10 | 10 × 8 | 10 × 5 | 15 × 15 |
| S3# | 9 | 0.96 | AE | 5 | 5 × 6 | 4 × 4 | 4 × 4 |
| S4* | 27 | 0.6 | AE, RS, Respi | 30 | 8 × 5 | 6 × 6 | 5 × 9 |
| S5# | 7 | 0.64 | AE | 30 | 5 × 5 | 5 × 5 | 5 × 5 |
| S6* | 30 | 2 | AE, GU, RS | 30 | 4 × 5 | 5 × 5 | 5 × 5 |
| S7# | 38 | 1.5 | AE, RS, Resp | 10 | 5 × 4 | 5 × 6 | 5 × 6 |
| S8* | 40 | 2 | AE, RS | 30 | 5 × 6 | 5 × 4 | 5 × 5 |
| S9* | 43 | 2 | Respi | 30 | 5 × 8 | 5 × 5 | 5 × 4 |
LU, localized urticaria; AE, angioedema; GU, generalized urticaria; RS, rhinorrhoea and bouts of sneezing; Resp, wheeze, dry persistent cough, or dyspnoea; GI, vomiting.
#
GOS allergic patients with historical clinical reactions.
*
Subjects have allergic symptoms upon vGOS oral challenge.